Investments of pharmaceutical enterprises of the SEZ Togliatti in 2021 amounted to 2.4 billion rubles. This is reported on the website of the SEZ Togliatti (Special Economic Zone of the industrial production type). New investors appear on the SEZ site.
Today, 29 residents are registered here, whose activity belongs to various sectors. 12 enterprises have already been launched, and the rest are being built or are at the project stage. According to Dmitry Bogdanov, the Minister of Economic Development and Investment of the Samara Region, the pharmaceutical cluster is successfully developing in the SEZ Togliatti, which is the runner-up there after the automotive component industries. The cluster’s production facilities employ 562 people.
“Ozon Pharm, Ozon Medica, Mabscale, SZMI, and Polypharm have already placed their enterprises on our flagship investment site. This year, the investments of these enterprises exceeded 2.4 billion rubles, and the revenue amounted to 1.1 billion rubles. In the second quarter of the year alone, these residents allocated 1.9 billion rubles for the development of their projects, which is 3.8 times more than the investments in the first quarter,” Dmitry Bogdanov said.
The healthcare direction at the SEZ has been noticeably reinforced by a new enterprise, Limited Liability Company Samara Plant of Medical Devices. The modern production facility opened in the SEZ in March, with the participation of Denis Manturov, the Minister of Industry and Trade of the Russian Federation, and Dmitry Azarov, the Governor of the Samara Region. The plant for the production of nitrile gloves is unique on a national scale: SZMI became the first such full-cycle production in Russia. 730 million rubles were invested in the construction of the plant.
“At the moment, together with the regional authorities, we are working on the issue of expanding SZMI’s production so that our products can be fully localized in Russia,” said Alexander Zemskov, the director of the enterprise.
As it became known earlier, Ozone Pharm launched its second line of medicines production in the SEZ Togliatti.
